Heidelberg, Germany – Affimed N.V. recently held their Q3 2024 Earnings Call, providing updates on their financial performance and corporate activities. The call, which took place on November 14, 2024, at 8:30 AM local time, featured key company personnel and analysts from various financial institutions.

The Company Participants included Alex Fudukidis, Head of Investor Relations & Director of Investor Relations; Shawn Leland, Chief Executive Officer; Andreas Harstrick, Chief Medical Officer; and Michael Wolf, Head of Finance & Administration. Additionally, Conference Call Participants from different firms like Cantor, Leerink Partners, and Wells Fargo were in attendance.

During the call, Alex Fudukidis, the host of the event, reminded participants that relevant press releases and presentations were accessible on the company’s Investor Relations website. He introduced other members of the management team, such as Wolfgang Fischer, Chief Operating Officer, and Denise Mueller, Chief Business Officer, who would be presenting the financial updates alongside VP of Finance, Michael Wolf.

Fudukidis also emphasized the importance of caution when interpreting the projections and forward-looking statements provided during the presentation, stating that they reflect the company’s beliefs and assumptions up to the date of the call. He highlighted that unless legally required, there is no obligation to update these statements in the future.

The call allowed for a thorough overview of Affimed’s performance during the third quarter of 2024 and offered insights into future strategies and initiatives. Following the prepared remarks, the management team engaged in a question and answer session, providing additional clarity on the company’s direction and financial outlook. Investors and analysts alike were attentive to the details shared during the call, indicating interest in Affimed’s trajectory in the biopharmaceutical sector.